ENG

MVITRO offers the most convenient
home care solutions for you.

We are an R&D company dedicated to developing medical devices and healthcare platforms tailored to the upcoming era of home care and remote medical consultations.
Maintaining health and living longer has become the utmost priority in today’s society. At MVITRO, we present to you unique and convenient healthcare solutions to enhance your quality of life.
Our research began by exploring novel methods to mitigate the limitations of traditional medical devices. We are committed to building a pre-diagnostic device and platform that empowers individuals to proactively gain a deeper understanding of their own bodies firsthand through innovative home care devices and physiological analyses previously unimagined. In line with the rapid pace of digital innovation in today’s society, we are striving to collaborate with various global companies to stay one step ahead. Our goal is to become a leading company in the global healthcare industry.

Join us in taking the next step toward a healthier, more convenient, and worry-free life.

COMPANY HISTORY

2017

2018 ~ 2019

2020 ~ 2022

2023

  • # MVITRO was established
  • # Started developing a medical device for diabetics
  • # Focused on making pain-free blood collectors
  • # Made MVITRO’s own laser technology more robust
  • # Integrated the laser technology with a blood glucose meter
  • # Started preparing for FDA approval in late 2022
  • # KES Innovation Award
  • # Applied to KFDA and FDA for ORTIV
  • # KAIST-NYU joint campus establishment fund donation
  • # CES 2023 participation
COMPANY HISTORY

  • 2017
  • # MVITRO was established
  • # Started developing a medical device for diabetics

  • 2018 ~ 2019
  • # Focused on making pain-free blood collectors
  • # Made MVITRO’s own laser technology more robust

  • 2020 ~ 2022
  • # Integrated the laser technology with a blood glucose meter
  • # Started preparing for FDA approval in late 2022
  • # KES Innovation Award

  • 2023
  • # Applied to KFDA and FDA for ORTIV
  • # KAIST-NYU joint campus establishment fund donation
  • # CES 2023 participation